IT

ITOXI Corp.

B2B platform for Ukraine-Korea trade, investment, and post-war reconstruction.

052770 | KO

Overview

Corporate Details

ISIN(s):
KR7052770005
LEI:
Country:
South Korea
Address:
서울특별시 강남구 도산대로 427 파모소빌딩 4층, 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

ITOXI Corp. is a diversified corporation, formerly known as YD Online Corp, with a history in the online and mobile game development industry. The company has expanded its business scope to include international business promotion and strategic partnership development. A key division, ITOXI UA, operates as a B2B platform facilitating cooperation, trade, and investment between Ukrainian and Korean companies. This platform offers end-to-end services including market research, partner sourcing and vetting, negotiation support, and project implementation for joint ventures and investment projects, with a particular focus on Ukraine's post-war reconstruction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Delisting Announcement
주권매매거래정지 (자본감소)
Korean 4.7 KB
2025-09-08 00:00
Share Issue/Capital Change
주요사항보고서(감자결정)
Korean 15.7 KB
2025-09-08 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 6.0 KB
2025-09-08 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-09-08 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(감자결정)
Korean 18.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.5 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-08-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 51.2 KB
2025-06-12 00:00
Share Issue/Capital Change
[정정명령부과][기재정정]주요사항보고서(전환사채권발행결정)
Korean 52.9 KB
2025-06-12 00:00
Share Issue/Capital Change
전환청구권행사 (제15회차)
Korean 9.6 KB
2025-06-05 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.8 KB
2025-05-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제17회차 CB)
Korean 6.1 KB
2025-05-19 00:00
Capital/Financing Update
[기재정정]주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 41.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all ITOXI Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ITOXI Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ITOXI Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.